Ovarian tissue cryopreservation after chemotherapy and successful pregnancy after autograft and additional chemotherapy

Background: Ovarian tissue cryopreservation (OTC) is a valid proce-dure that may allow to preserve endocrine and reproductive health in girls and young women at high risk of premature ovarian failure. At disease remission, the OTC may be transplanted in the woman, allowing recovery of the production of oocytes and repro-ductive hormones. Case: This report describes the case of a Ewing Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET) survivor who cryopreserved ovarian tissue after the first line of chemotherapy. After completion of treatment the patient experienced premature ovarian failure. Seven years later ovarian tissue autotransplantation was performed and ovarian function recovery was obtained in a few months. The woman had a shoulder ES/PNET recurrence and restarted the chemotherapy. The menstrual cycle reappeared 4 months after the second line of treatment and the patient spontaneously conceived 10 months later giving birth to a healthy girl. Conclusions: In malignancies OTC performed even after the start of chemotherapy seems to be effective in preserving fertility and allows more women to become candidates for ovarian function preservation.

Ovarian tissue cryopreservation; Ovarian tissue transplantation; Ewing sarcoma; Recurrence; Live birth

[1] Jeong K, Aslan E, Ozkaya E, Sonmezer M, Oktay K. Ovarian cryopreservation. Minerva Medica. 2012; 103: 37–46.

[2] Dolmans M, Donnez J. Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue. Best Practice & Research Clinical Obstetrics & Gynaecology. 2021; 70: 63–80.

[3] Donnez J, Dolmans M. Fertility Preservation in Women. The New England Journal of Medicine. 2017; 377: 1657–1665.

[4] Paradisi R, Fabbri R, Magnani V, Battaglia C, Venturoli S. A new simple technique of laparoscopic temporary ovarian suspension in addition to ovarian cryopreservation for women prior to posterior pelvic radiation. Gynecologic Oncology. 2010; 117: 385–386.

[5] Fabbri R, Pasquinelli G, Keane D, Magnani V, Paradisi R, Venturoli S. Optimization of protocols for human ovarian tissue cryopreservation with sucrose, 1,2-propanediol and human serum. Reproductive BioMedicine Online. 2010; 21: 819–828.

[6] Fabbri R, Vicenti R, Macciocca M, Martino NA, Dell’Aquila ME, Pasquinelli G, et al. Morphological, ultrastructural and functional imaging of frozen/thawed and vitrified/warmed human ovarian tissue retrieved from oncological patients. Human Reproduction. 2016; 31: 1838–1849.

[7] Fabbri R, Pasquinelli G, Magnani V, Macciocca M, Vicenti R, Parazza I, et al. Autotransplantation of cryopreserved ovarian tissue in oncological patients: recovery of ovarian function. Future Oncology. 2014; 10: 549–561.

[8] Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Human Reproduction. 2007; 22: 1626–1633.

[9] Abir R, Ben-Haroush A, Felz C, Okon E, Raanani H, Orvieto R, et al. Selection of patients before and after anticancer treatment for ovarian cryopreservation. Human Reproduction. 2008; 23: 869–877.

[10] Poirot C, Fortin A, Lacorte JM, Akakpo JP, Genestie C, Vernant JP, et al. Impact of cancer chemotherapy before ovarian cortex cry-opreservation on ovarian tissue transplantation. Human Reproduction. 2019; 34: 1083–1094.

[11] Peter M, Magdelenat H, Michon J, Melot T, Oberlin O, Zucker JM, et al. Sensitive detection of occult Ewing’s cells by the reverse transcriptase-polymerase chain reaction. British Journal of Cancer. 1995; 72: 96–100.

[12] Pfleiderer C, Zoubek A, Gruber B, Kronberger M, Ambros PF, Lion T, et al. Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. International Journal of Cancer. 1995; 64: 135–139.

[13] West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. Journal of Clinical Oncology. 1997; 15: 583–588.

[14] Avigad S, Cohen IJ, Zilberstein J, Liberzon E, Goshen Y, Ash S, et al. The predictive potential of molecular detection in the non-metastatic Ewing family of tumors. Cancer. 2004; 100: 1053–1058.

[15] Greve T, Timmermans Wielenga V, Grauslund M, Sørensen N, Christiansen DB, Rosendahl M, et al. Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumor cell contamination. European Journal of Cancer. 2013; 49: 1932–1938.

[16] Yding Andersen C, Ernst E, Bærentzen S, Birkebæk NH, Clausen N. No malignancy detected in surplus ovarian tissue from a former Ewing sarcoma patient who experienced relapse four years after being grafted with frozen/thawed ovarian tissue. Journal of Assisted Reproduction and Genetics. 2014; 31: 1567–1568.

[17] Abir R, Feinmesser M, Yaniv I, Fisch B, Cohen IJ, Ben-Haroush A, et al. Occasional involvement of the ovary in Ewing sarcoma. Human Reproduction. 2010; 25: 1708–1712.

[18] Sørensen SD, Greve T, Timmermans Wielenga V, Wallace WHB, Andersen YC. Safety considerations for transplanting frozen/thawed ovarian tissue to restore fertility in patientswho have recovered from Ewing sarcoma. Future Oncology. 2014; 10: 277–283.

[19] Benini S, Gamberi G, Cocchi S, Garbetta J, Alberti L, Righi A, et al. Detection of circulating tumor cells in liquid biopsy from Ew-ing sarcoma patients. Cancer Management and Research. 2018; 10: 49–60.

[20] Meirow D, Ra’anani H, Shapira M, Brenghausen M, Derech Chaim S, Aviel-Ronen S, et al. Transplantations of frozenthawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertility and Sterility. 2016; 106: 467–474.